Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors

Historically, molecular imaging of somatostatin receptor (SSTR) expression in patients with neuroendocrine tumors (NET) was performed using SSTR scintigraphy (SRS). Sustained advances medical have led to its gradual replacement positron-emission tomography (SSTR-PET). The higher sensitivity comparison SRS on the one hand and conventional cross-sectional imaging, other hand, enables more accurate staging allows for image quantification. In addition, recent years, a growing body evidence has assessed prognostic implications SSTR-PET-derived biomarkers NET patients, aim risk stratification, outcome prognostication, prediction response peptide radionuclide therapy. this narrative review, we give an overview studies examining value advanced (semi-)quantitative metrics like tumor volume, uptake, composite metrics. Complementing analysis, discussion current trends, clinical implications, future directions is provided.